Wave Life Sciences Ltd.

NASDAQ:WVE

Biotechnology

Healthcare
$2.84 +1.63%

+$0.10 today

Market cap
$560.13M
Beta
-1.33
P/E (TTM)
-6.6
EPS (TTM)
-$0.92
52W Low $5.02High $21.73

Volume 2.78M

Average 4.86M

WVE Operating Margin

Operating income as a percentage of revenue, showing the profitability of core operations.

Wave Life Sciences Ltd.NASDAQ: WVE

Operating Margin · Q1 FY2026 · quarter ended Mar 2026

Operating margin widens to -81.8%

Operating margin was -81.8% in Q1 FY2026, up 461.0 pp from a year earlier. On a trailing-twelve-month basis it was -274.2%, down 154.4 pp year over year. Over 3 fiscal years it widened by 3955.2 pp.

Context

  • Operating margin widened in 1 of the last 3 fiscal years.

What to watch

Whether operating margin reaches the consensus estimate from 15 analysts of -273.0% for the fiscal year ending Dec 2026, up from -504.1% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-81.8%+245.6 pp QoQ
Last fiscal yearDec 2025
-504.1%-402.2 pp YoY
LTMMar 2026
-274.2%-154.4 pp YoY
Operating Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+461.0 pp-215.2 pp-676.2 pp
1 year-402.2 pp+231.1 pp+633.2 pp
3 years+3955.2 pp-50.9 pp-4006.1 pp
5 years+489.2 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

Operating Margin history

Percent of revenue · from the income statement

Latest · FY2025
-504.1%
Year-over-year change
-402.2pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

Operating Margin vs competitors

How WVE compares with its peers on the latest reported figures

  • WVE's LTM Mar 2026 operating margin of -274.2% is the 6th highest of the 10 companies compared; the peer median is -196.7%.
  • Its year-over-year change of -154.4 pp is the 6th highest of 9, against a peer median of -83.1 pp.
  • Over three fiscal years its change of +3955.2 pp compares with a peer median of +29.4 pp.
WVE Competitors Peer median
Operating Margin for WVE and competitors
Company Period LTM level YoY 3-year change
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 202620.8% +28.1 pp+89.2 pp
SRPTSarepta Therapeutics, Inc.LTM Mar 2026-1.9% +3.4 pp+27.5 pp
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026-58.9% -30.2 pp+29.4 pp
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026-156.9% -168.7 pp-71.7 pp
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026-196.7% -136.0 pp-117.4 pp
WVEWave Life Sciences Ltd.LTM Mar 2026-274.2% -154.4 pp+3955.2 pp
PRQRProQR Therapeutics N.V.LTM Mar 2026-345.5% -170.5 pp+1537.1 pp
STOKStoke Therapeutics, Inc.LTM Mar 2026-577.5% -597.5 pp+830.1 pp
NTLAIntellia Therapeutics, Inc.LTM Mar 2026-636.6% +550.8 pp+227.4 pp
SLNSilence Therapeutics plcLTM Mar 2026-9396.6% —-15774.1 pp
BNTCBenitec Biopharma Inc.FY2025— ——
Peer median (excluding WVE) -196.7%-83.1 pp+29.4 pp

Competitors are the stored peer set for WVE. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue40.96M3.65M113.31M108.3M42.73M
Cost of Revenue00008.85M
Gross Profit40.96M3.65M113.31M108.3M33.88M
Gross Margin100.0%100.0%100.0%100.0%79.3%
Research & Development121.88M115.86M130.01M159.68M182.78M
Selling, General & Admin46.11M50.51M51.29M59.02M75.33M
Operating Expenses167.98M166.37M181.3M218.71M249.26M
Depreciation & Amortization9.84M10.11M9.21M8.66M8.85M
EBITDA(112.61M)(151.03M)(48.98M)(88.35M)(195.53M)
EBITDA Margin-274.9%-4138.9%-43.2%-81.6%-457.6%
Operating Income(127.02M)(162.72M)(68M)(110.4M)(215.38M)
Operating Margin-310.1%-4459.3%-60.0%-101.9%-504.1%
Interest Income30K00010.48M
Interest Expense00000
Other Income / Expenses4.57M1.58M9.81M13.4M11.01M
Income Before Tax(122.45M)(161.14M)(58.19M)(97.01M)(204.38M)
Pre-Tax Margin-298.9%-4416.1%-51.4%-89.6%-478.3%
Income Tax Expense(204K)681K(677K)00
Net Income(122.25M)(161.82M)(57.51M)(97.01M)(204.38M)
Net Margin-298.4%-4434.7%-50.8%-89.6%-478.3%
EPS (Basic)(2.36)(2.05)(0.54)(0.70)(1.21)
EPS (Diluted)(2.36)(2.05)(0.54)(0.70)(1.21)
Weighted Avg Shares51.83M78.86M106.1M138.28M168.65M
Weighted Avg Shares (Diluted)51.83M78.86M106.1M138.28M168.65M

Wave Life Sciences Ltd.

NASDAQ:WVE

Intrinsic Alpha fair value

Locked

Current Price

$2.84

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.